CDK8/19-IN-2
Product Specifications
UNSPSC Description
CDK8/19-IN-2 (compound 12) is an orally active and potent cyclin-dependent kinase 8/19 (CDK8 and CDK19) inhibitor, with IC50 values of 2.08 and 2.49 nM, respectively. CDK8/19-IN-2 can be used for acute myeloid leukemia (AML), breast cancer, and lymphoma research[1].
Target Antigen
CDK; STAT
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage;JAK/STAT Signaling;Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk8-19-in-2.html
Smiles
BrC1=C(C=C2N(C(N3CCNCC3)=NC2=C1C(F)F)C4CCOCC4)Br
Molecular Weight
494.17
References & Citations
[1]Xu J, et al. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer. J Med Chem. 2024 May 23;67(10):8161-8171.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-158377/CDK8-19-IN-2-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-158377/
Clinical Information
No Development Reported
CAS Number
3024381-54-9
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
ARP60873_P050-FITC 100 µL
HIST1H2AH Antibody - C-terminal region: FITC (ARP60873_P050-FITC)
Ask
View Details 
MBS6177920-01 0.1 mL
FAF1 (Fas (TNFRSF6) Associated Factor 1, CGI-03, FLJ37524, HFAF1s, UBXD12, UBXN3A, hFAF1) (FITC)
Ask
View Details